Ammar Sabilarrohman
The Committee on pharmaceutical affairs has issued a comprehensive set of policy recommendations aimed at bolstering Taiwan’s healthcare infrastructure, ensuring the long-term viability of the National Health Insurance (NHI) system, and enhancing the nation’s standing in the global biotechnology market. In a detailed position paper released to government stakeholders, the Committee emphasized that as global political and economic landscapes shift, Taiwan must adapt its drug pricing structures and regulatory frameworks to maintain supply stability and ensure that patients have timely access to life-saving innovative therapies. The report comes at a pivotal moment in Taiwan-U.S. relations, particularly as the administration of President Lai Ching-te seeks to position biotechnology as one of the "Five Trusted Industries" critical to the island’s economic and strategic future. By fostering deeper public-private partnerships and aligning domestic practices with international standards, the Committee argues that Taiwan can transition from a reactive healthcare model to a proactive, resilient, and globally competitive ecosystem.
Strengthening the U.S.-Taiwan Strategic Pharmaceutical Partnership
Central to the Committee’s recommendations is the formalization of a structured U.S.-Taiwan pharmaceutical policy dialogue mechanism. This proposal builds upon recent breakthroughs in bilateral trade, most notably the agreement that granted duty-free treatment in the United States market for Taiwanese generic drugs and active pharmaceutical ingredients (APIs). While these tariff reductions represent a significant milestone, the Committee asserts that a more institutionalized framework is necessary to navigate the complexities of modern drug development and supply chain management.
The proposed dialogue would serve as a platform for regular, high-level exchanges between government representatives from both nations, alongside industry experts, scholars, and manufacturers. Key topics for these consultations would include the introduction of innovative medicines, regulatory harmonization, and evolving pricing trends. To ensure the effectiveness of this platform, the Committee suggests that the National Health Insurance Administration (NHIA) conduct biannual consultations with the private sector. These meetings would allow for a joint review of global economic shifts and pharmaceutical pricing developments, ensuring that Taiwan’s policies remain responsive to international market realities.
Beyond bilateral cooperation, the Committee advocates for leveraging the Global Cooperation and Training Framework (GCTF). By utilizing this existing initiative, Taiwan can share its healthcare governance expertise with a broader array of global partners, showcasing its strengths in medical technology and public health management. This move is seen as essential for integrating Taiwan more deeply into the global healthcare community and attracting foreign direct investment (FDI) into the domestic biotech sector.
Aligning Reimbursement with International Clinical Guidelines
A significant portion of the report focuses on the disparity between Taiwan’s current drug reimbursement conditions and international treatment standards. While the Committee lauded the "Healthy Taiwan" policy vision—a national initiative spearheaded by the current administration to improve cancer care—it noted that substantial gaps remain for non-cancer treatments and even certain advanced oncology therapies.
Currently, many medicines in Taiwan face restrictive reimbursement criteria, such as limitations on the eligible patient population, mandates for specific prior lines of treatment, or constraints on dosing and duration. The Committee warns that this misalignment does more than just limit physician autonomy; it creates a "clinical experience gap." When local reimbursement does not match global standards, Taiwan becomes a less attractive site for international clinical trials. This, in turn, reduces opportunities for Taiwanese researchers to collaborate on cutting-edge studies and delays the accumulation of local clinical data, ultimately undermining the global competitiveness of the domestic healthcare system. To rectify this, the government is urged to accelerate the alignment of reimbursement conditions across all disease areas with international treatment guidelines, ensuring that Taiwanese patients receive care that is on par with the best available globally.
The 2025 Cancer Drugs Fund and Evidence-Based Funding
In a move welcomed by the pharmaceutical industry, the Taiwan government has committed to establishing a dedicated Cancer Drugs Fund in 2025. This fund is expected to reach approximately NT$10 billion (US$310 million) once fully operational. The Committee views this as a vital step toward improving access to high-cost innovative therapies. However, the report stresses that the success of such a fund depends on how it is managed and integrated into the broader NHI system.
The Committee recommends that budgeting for new drug expenditures should move away from relying on isolated data points and instead adopt a medium-to-long-term outlook. This approach would involve "horizon scanning"—a systematic process of analyzing emerging trends and clinical pipelines to anticipate future healthcare needs. By using these predictive tools, the NHIA can make more informed decisions about resource allocation, ensuring that funding is both adequate and precise.
Furthermore, the Committee highlighted the importance of maintaining pricing premiums for drugs that undergo clinical trials within Taiwan. Such incentives are crucial for attracting multinational pharmaceutical companies to conduct R&D locally. If these incentives are diluted in future regulatory revisions, the Committee warns that Taiwan may lose its appeal as a regional hub for pharmaceutical innovation, potentially leading to delays in the domestic launch of new therapies.
Reforming Drug Pricing and Market Access Strategies
The global pharmaceutical market is currently undergoing a period of intense recalibration. Multinational corporations are increasingly scrutinizing national pricing structures to determine where to prioritize new drug launches. In this context, Taiwan’s pricing framework has come under fire for being overly restrictive. The Committee recommends that the NHI Pharmaceutical Reimbursement and Payment Standards be updated to reflect the median price of 10 reference countries, rather than the lowest common denominator.
Additionally, the report calls for value-based price adjustments. This means that drug prices should reflect not just the cost of production, but also the clinical effectiveness, safety profile, convenience of administration, and potential for pediatric use. The Committee also emphasized the need for clear pricing premiums for medicines that address urgent unmet medical needs or are critical to supply resilience.
A particularly contentious issue raised in the report is the use of pharmaceutical reimbursement agreements (PRAs). While PRAs are useful tools for managing budget impacts, the Committee noted that current implementations often prioritize short-term financial controls, such as high rebate requirements and hard spending caps. Because many countries now use international reference pricing, an excessively low net price in Taiwan can negatively impact a drug’s pricing strategy in other, larger markets. If Taiwan’s prices are too compressed, global headquarters may de-prioritize the island for new product launches. The Committee advocates for a PRA framework based on procedural fairness, reasonable risk-sharing, and strict confidentiality to maintain Taiwan’s market attractiveness.
Chronology of Taiwan’s Pharmaceutical Policy Evolution
The current recommendations sit at the end of a multi-year timeline of healthcare reform in Taiwan. In the early 2010s, the Drug Expenditure Target (DET) system was introduced as a pilot program to control the growing costs of the NHI. However, the baseline for these calculations has not been updated in over a decade, leading to what the Committee describes as "distorted pricing signals."
In 2023, the Ministry of Health and Welfare (MOHW) and the NHIA made several public commitments to improve the drug pricing framework. This was followed by the landmark amendment to Article 27 of the Pharmaceutical Affairs Act, which shifted the government’s approach from reacting to drug shortages to proactive risk management. As Taiwan enters 2025, the launch of the Cancer Drugs Fund and the ongoing negotiations under the U.S.-Taiwan Initiative on 21st-Century Trade represent the latest chapters in this evolution.
Enhancing Supply Resilience and Lifecycle Management
The final pillar of the Committee’s report addresses the lifecycle management of pharmaceutical products. One of the primary concerns is the protection of intellectual property rights (IPR). Currently, Taiwan provides price protection primarily to drugs with primary active-ingredient patents. The Committee argues that this is inconsistent with international standards, which often recognize a broader scope of secondary patents. When innovative medicines lose price protection despite holding valid patents, it undermines their lifecycle value and discourages companies from bringing future innovations to the market.
Regarding supply resilience, the Committee expressed concern over the implementation of the amended Pharmaceutical Affairs Act. While the goal of proactive risk management is noble, the associated regulations could impose significant administrative burdens on manufacturers. The Committee recommends a risk-based approach, where products with stable supply chains are subject to less frequent reporting requirements. Importantly, the report insists that forecast data provided by companies should be used for monitoring purposes only and should not be used as a basis for punitive measures.
Broader Implications for the Taiwan Healthcare Ecosystem
The implications of these recommendations extend far beyond the balance sheets of pharmaceutical companies. At its core, the Committee’s report is about the sustainability of the Taiwanese social contract. The NHI is a pillar of Taiwanese society, providing universal coverage to over 23 million people. However, as the population ages and the cost of innovative therapies rises, the system faces an existential financial challenge.
Failure to address the pricing and reimbursement gaps highlighted by the Committee could lead to a "two-tier" healthcare system, where only those who can afford out-of-pocket payments have access to the latest medical breakthroughs. Furthermore, by failing to align with international standards, Taiwan risks being sidelined in the global biotech revolution, losing out on both economic investment and the clinical expertise that comes with it.
By adopting a more transparent, predictable, and internationally aligned pharmaceutical policy, the Committee believes Taiwan can secure its supply chains, protect its patients, and fulfill its ambition of becoming a "Trusted Industry" leader in the global biotechnology landscape. The ball is now in the government’s court to transform these recommendations into actionable policy.
Sagoh
Nila Kartika Wati
